TheraSphere™

Y-90 Glass Microspheres

Product Description

TheraSphere is a targeted HCC therapy consisting of millions of glass microspheres containing radioactive Yttrium-90 (Y-90). TheraSphere allows for personalization of treatment and greater flexibility by offering a multitude of standard and custom dose vial options to meet individual patient treatment goals. TheraSphere has demonstrated treatment success in a range of scenarios: curative or palliative, livers with single or multifocal tumors, portal vein thrombosis (PVT), and using subsegmental, segmental or lobar approaches1-8.

Strike first with three distinct advantages. We have a proven therapy to fight cancer* at every stage.8 We deploy a custom personalized dose to extend life, to improve life. We act with expert precision.

Proven:
TheraSphere has demonstrated success in a range of scenarios: curative intent or palliative treatment, livers with single or multifocal tumors, with or without portal vein thrombosis (PVT)1-6.


Personalized:
Personalized dosimetry has a high correlation with overall survival7. Each dose arrives ready to deploy and is calculated for each patient, every time. For maximum tumor response.


Precise:
Shrink and destroy liver tumors with precisely formulated, highly powerful glass microspheres, deployed with pinpoint precision.

*Refers to HCC (Liver Cancer)

  1. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741–9
  2. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163–71 
  3. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826–37 
  4. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60(1):192–201
  5. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507
  6. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920–8
  7. Garin et al, J Clin Oncol 38, 2020 (suppl 4; abstr 516)
  8. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.

 

Top